Sector News

New vaccine for Ebola among CHMP recommendations

June 2, 2020
Life sciences

Johnson and Johnson’s experimental two-stage vaccine for protection against Ebola virus disease is among eight medicines backed by the European Medicines Agency’s human medicines committee (CHMP) at its May meeting.

The vaccine, developed by J&J group Janssen, provides active immunisation to prevent Ebola virus disease (Zaire ebolavirus species) in individuals aged one year and older.

It consists of two components, Zabdeno (Ad26.ZEBOV), which is given first, and Mvabea (MVA-BN-Filo), given around eight weeks later.

Zabdeno and Mvabea received a positive opinion for marketing authorisations under exceptional circumstances ‘because the applicant was able to demonstrate that it is not possible to conduct a randomised controlled study that might generate comprehensive clinical data on the efficacy of the new Ebola vaccine even after authorisation’, the agency noted.

Elsewhere, the following medicines also took giant leap closer to EU approval:

  • MYR’s Hepcludex (bulevirtide), for the treatment of chronic hepatitis delta virus infection in adult patients with compensated liver disease. Because there are no treatments currently approved for hepatitis D;
  • Novartis’ Piqray (alpelisib)for the treatment of locally advanced or metastatic breast cancer with a PIK3CA mutation.
  • Roche’s Rozlytrek (entrectinib; conditional marketing authorisation), for the treatment of patients whose solid tumours have a neurotrophic tyrosine receptor kinase gene fusion, or patients with ROS1-positive advanced non-small cell lung cancer;
  • Nabriva Therapeutics Ireland’s Xenleta (lefamulin)for the treatment of community-acquired pneumonia in adults;
  • Accord Healthcare’s biosimilar Zercepac (trastuzumab)for the treatment of breast and gastric cancer; and
  • Accord’s generic Apixaban Accord (apixaban)for treatment and prevention of venous thromboembolic events in adult patients and for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.

By: Selina McKee

Source: Pharma Times

Related News

July 7, 2020

Novartis banks EC approval for Enerzair Breezhaler

Life sciences

The European Commission (EC) has approved Novartis’ Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate) for uncontrolled asthma. More specifically, the drug has been cleared as a maintenance treatment […]

July 7, 2020

Sanofi, GlaxoSmithKline near $625M COVID-19 vaccine supply deal with U.K. government: report

Life sciences

As COVID-19 vaccines near final stages of testing, governments are also racing against each other, busy securing supply for their own countries even before key efficacy data readouts. After signing […]

July 7, 2020

J&J expands COVID-19 vaccine pact with Catalent for finishing work at Italian facility

Life sciences

Johnson & Johnson has been on a manufacturing deal spree as it nears human trials for its COVID-19 vaccine hopeful. On the same day it inked a $480 order from […]